Revive Therapeutics INC.
pharmaceutical and therapeutics manufacturer
AI Overview
With $115K in lobbying spend across 11 quarterly filings, Revive Therapeutics INC is an active lobbying client. Their lobbying covers 1 issue area. Active from 2021 to 2023.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2021 | $90K |
| 2022 | $25K |
| 2023 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Revive Therapeutics INC. disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues
Advocating for acceleration and approval of bucillamine as a COVID-19 critical therapeutic solution. In addition, advocating for TBI, PTSD applications of other medicines in development.
Advocating for assistance w/Phase 3 trial for Bucillamine
Advocating for assistance w/Phase 3 trial for Bucillamine, educating Members of Congress, BARDA/HHS and NIH regarding Bucillamine as a repurposed drug for COVID19.
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.